TP53 and endometrial carcinoma: Recently, the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) molecular classifier has shown prognostic value in endometrial carcinoma (12); for example, a study showed that TP53-mutated tumors were associated with poor prognosis, independently of the International Federation of Gynecology and Obstetrics (FIGO) stage and histological grade (13).